Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples